- Abatacept for rheumatoid arthritis2011 | Faculty of Medicine in Hradec Králové
- Abatacept in the treatment of rheumatoid arthritis.2008 | First Faculty of Medicine
- Excellent therapeutical effect of abatacept (Orencia) in RA patient previously unsuccessfully treated with infliximab (Remicade)2010 | Publication without faculty affiliation
- Abatacept – new biological drug for rheumatoid arthritis treatment.2008 | First Faculty of Medicine
- Immunogenicity and predicitve factors for biological therapy treatment in rehumatoid arthritis - focused on abatacept2016 | First Faculty of Medicine
- Abatacept in the treatment of rheumatoid arthritis2007 | First Faculty of Medicine
- Abatacept - new biologic drug for therapy of rheumaotid arthritis2007 | First Faculty of Medicine
- Abatacept and its use in Czech republic in treatment of RA – results from registry ATTRA2012 | First Faculty of Medicine
- Biological treatment of RA: a double entrance, one succes2011 | Faculty of Medicine in Hradec Králové
- Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry2013 | First Faculty of Medicine
- Účinnost abataceptu v léčbě revmatoidní artritidy v každodenní praxi2016 | Third Faculty of Medicine
- Prognostické faktory pro setrvání na abataceptu po předchozí biologické léčbě2016 | Third Faculty of Medicine
- Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study2016 | First Faculty of Medicine
- Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study2014 | First Faculty of Medicine
- Safety of biological treatment – recommendations of Czech Society for Rheumatology.2009 | First Faculty of Medicine
- Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study2015 | First Faculty of Medicine
- Biological therapy in Rheumatology2016 | First Faculty of Medicine
- Temporal arteritis - pitfalls in diagnosis and treatment2019 | First Faculty of Medicine
- Recurrent focal segmental glomerulosclerosis in the transplanted kidney2017 | Faculty of Medicine in Pilsen
- Biologics in the treatment of rheumatoid arthritis2014 | First Faculty of Medicine
- Adverse effects of biological therapy in rheumatology2014 | First Faculty of Medicine
- Present and future of biological therapies for rheumatoid arthritis - a dilemma of choice +12015 | Publication without faculty affiliation
- Postavení biologické terapie v léčbě revmatoidní artritidy2015 | First Faculty of Medicine
- New Pharmacotherapeutic Possibilities in Contemporary Dentistry2015 | Faculty of Medicine in Hradec Králové
- Therapeutic options for CTLA-4 Insufficiency2022 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution2019 | First Faculty of Medicine
- Safety of biological therapy - guidelines of the Czech Society for Rheumatology +12009 | Faculty of Medicine in Hradec Králové
- Biological treatment in rheumatology2010 | First Faculty of Medicine